Should you buy, sell or hold PNB, NTPC, PowerGrid, Zomato, JSW Steel shares?
Which stocks to buy, hold or sell today? As Dalal Street enters the May 22 session, heres a look at what brokerages make of some of the key stocks in focus. On their radar are stocks such as Punjab National Bank, Zomato, PowerGrid, NTPC and JSW Steel.
Which stocks to buy, hold or sell today? As Dalal Street enters the May 22 session, here's a look at what brokerages make of some of the key stocks in focus. On their radar are scrips such as Punjab National Bank (PNB), JSW Steel, PowerGrid, NTPC and Zomato.
Do you have any of these stocks in your portfolio?
PNB shares
Brokerage | Rating | Target price |
Morgan Stanley | Underweight | Rs 55 |
JPMorgan | Overweight | Rs 72 |
Citi | Sell | Raised to Rs 42 from Rs 41 |
Jefferies | Hold | Rs 54 |
PowerGrid shares
CLSA maintained an 'outperform' rating on PowerGrid but reduced its target price by Rs 4 to Rs 255.
Morgan Stanley continued with 'overweight' with a target of Rs 258.
Zomato shares
Brokerage | Rating | Target price |
CLSA | Buy | Raised to Rs 80 from Rs 70 |
Morgan Stanley | Overweight | Raised to Rs 85 from Rs 74 |
JPMorgan | Overweight | Reduced to Rs 90 from Rs 100 |
Citi | Buy | Raised to RS 84 from Rs 76 |
Jefferies | Buy | Rs 100 |
Goldman Sachs | Buy | Raised to Rs 82 from Rs 80 |
Nomura | Reduce | Rs 45 |
HSBC | Buy | Raised to Rs 88 from Rs 87 |
Credit Suisse | Outperform | Rs 82 |
According to Goldman Sachs, Zomato's Q4 results and latest management commentary were better than its expectations, on the back of improving growth and profit outlook.
JSW Steel shares
Brokerage | Rating | Target price |
CLSA | sell | Raised to Rs 655 from Rs 640 |
Morgan Stanley | Underweight | Rs 580 |
Jefferies | Underperform | Raised to Rs 510 from Rs 470 |
Citi | Sell | Reduced to Rs 600 from Rs 675 |
Nomura | Reduce | Raised to Rs 605 from Rs 570 |
NTPC shares
CLSA retained a 'buy' call on NTPC with a target price of Rs 209.
Morgan Stanley continued with 'overweight' with a target of Rs 198.
Divi's Labs shares
According to Jefferies, which upgraded Divi's Laboratories to 'buy' from 'underperform', believes the drug maker should in on track to achieving revenue growth in mid or high teens from the quarter ending September 2023. The brokerage raised its target price for the pharma company's stock to Rs 3,610 from Rs 2,550.
Divi's Labs' revenue and EBITDA for the quarter ended March 2023 was ahead of the brokerage's estimates.
Goldman Sachs maintained a 'buy' rating on Divi's but reduced its target to Rs 3,400 from Rs 3,500.
Bandhan Bank
Brokerage | Rating | Target price |
CLSA | Buy | Rs 320 |
Jefferies | Buy | Rs 340 |
Goldman Sachs | Buy | Raised to Rs 294 from Rs 269 |
Nomura | Buy | Reduced to Rs 310 from Rs 320 |
Muthoot Finance shares
CLSA continued with 'reduce' on Muthoot Finance with a target of Rs 1,140.
MCX shares
Morgan Stanley retained its 'underweight' call on MCX with a target price of Rs 1,125.
Catch latest stock market updates here. For all other news related to business, politics, tech, sports and auto, visit Zeebiz.com.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.